Newron Pharmaceuticals SpA (XSWX:NWRN) Valuation Rank


XSWX:NWRN Newron Pharmaceuticals SpA XSWX:NWRN
64 GF Score
Price CHF12.76
GF Value CHF12.97
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Newron Pharmaceuticals SpA Valuation Rank Related Terms

XSWX:NWRN
64GF Score
Newron Pharmaceuticals SpA XSWX:NWRN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of CHF12.76 is trading 1.6% below its estimated GF Value™ of CHF12.97. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for XSWX:NWRN:

  • Valuation Rank:
  • GF Value™: CHF12.97 vs. price of CHF12.76 (1.6% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Other Exchanges NWRNz:UK0QOI:UKNP5:Germany
Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for XSWX:NWRN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF12.76
Price
CHF12.97
GF Value